Scaling Alzheimer's Care: The Case for Specialized Treatment Clinics

The approval of amyloid-targeting monoclonal antibodies has transformed Alzheimer's disease (AD) treatment, shifting the field from symptomatic management to targeting the underlying pathology. These therapies require specialized care models to manage the selection, treatment, and monitoring of eligible patients.

Here, we describe the implementation of the Anti-Amyloid Treatment Clinic (KU-AATC) at the University of Kansas Health System, a dedicated clinic model designed to streamline access to amyloid-clearing therapies and to provide safe, efficient patient care. We detail the KU-AATC's structured approach, including a multidisciplinary team with advanced practice providers (APPs), leading patient evaluation and shared decision-making, and tailored workflows to ensure timely access to treatment. We review data from the clinic's first 18 months.

The KU-AATC model demonstrates a feasible approach to managing the complex needs of amyloid-targeting therapy for AD.

Our findings suggest that a specialized clinic structure can support safe, accessible, and efficient care for AD patients, potentially serving as a scalable model for healthcare systems adapting to the demands of emerging AD treatments. Expanding similar clinics may address neurologist shortages and improve equitable access to advanced therapies.